» Articles » PMID: 20005786

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Regulates the Production of Osteoprotegerin (OPG) and Prostaglandin (PG) E2 in Human Bone

Overview
Journal J Cyst Fibros
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2009 Dec 17
PMID 20005786
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Bone loss is an important clinical issue in patients with cystic fibrosis (CF). Whether the cystic fibrosis transmembrane conductance regulator (CFTR) plays a direct role in bone cell function is yet unknown. In this study, we provide evidence that inhibition of CFTR-Cl(-) channel function results in a significant decrease of osteoprotegerin (OPG) secretion accompanied with a concomitant increase of prostaglandin (PG) E(2) secretion of primary human osteoblast cultures (n=5). Our data therefore suggest that in bone cells of CF patients, the loss of CFTR activity may result in an increased inflammation-driven bone resorption (through both the reduced OPG and increased PGE(2) production), and thus might contribute to the early bone loss reported in young children with CF.

Citing Articles

Changes in bone turnover after high-dose vitamin D supplementation during acute pulmonary exacerbation in cystic fibrosis.

Wu M, Bhimavarapu A, Alvarez J, Hunt W, Tangpricha V Bone. 2023; 174:116835.

PMID: 37390941 PMC: 10428002. DOI: 10.1016/j.bone.2023.116835.


Cystic Fibrosis Bone Disease: The Interplay between CFTR Dysfunction and Chronic Inflammation.

Fonseca O, Gomes M, Amorim M, Gomes A Biomolecules. 2023; 13(3).

PMID: 36979360 PMC: 10046889. DOI: 10.3390/biom13030425.


Bisphosphonates for osteoporosis in people with cystic fibrosis.

Jeffery T, Chang A, Conwell L Cochrane Database Syst Rev. 2023; 1:CD002010.

PMID: 36625789 PMC: 9831115. DOI: 10.1002/14651858.CD002010.pub5.


Auxological and Endocrinological Features in Children and Adolescents with Cystic Fibrosis.

Ferrari V, Terlizzi V, Stagi S J Clin Med. 2022; 11(14).

PMID: 35887806 PMC: 9323690. DOI: 10.3390/jcm11144041.


Receptor Specificity Engineering of TNF Superfamily Ligands.

Suo F, Zhou X, Setroikromo R, Quax W Pharmaceutics. 2022; 14(1).

PMID: 35057080 PMC: 8781899. DOI: 10.3390/pharmaceutics14010181.